Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs GeneDx Holdings Corp — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $78.97, while GeneDx Holdings Corp trades at $60.5 (market cap $1.80B). The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| IEMG | WGS | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $86.00 | $167.51 |
52-Week Low | $59.90 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $77.21, up 0.3% with a bearish technical signal from moving averages and oscillators. The ETF shows strong recent performance with 35% gains over the past year, driven by emerging market inflows and AI-focused technology exposure. Recent news highlights record capital flows into emerging markets and IEMG's 40% technology weighting, though some analysts caution about elevated volatility and concentration risks.
The outlook remains mixed with attractive emerging market valuations and growth opportunities balanced against geopolitical risks and market volatility. Key catalysts include continued AI-driven technology performance and emerging market economic growth, while risks involve US-China tensions and potential market corrections given the ETF's recent strong run.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
